电邮这篇文章 Opportunities of metabolic treatment in paroxysmal atrial fibrillation patients with obesity, arterial hypertension and/or ischemic heart disease
- 作者: Balabanovich T.I.1, Golyshko V.S.1, Sinkevich I.A.2, Shkuta E.S.2, Veniadziktova E.A.2, Baliuk P.V.2, Knysh A.V.2
-
隶属关系:
- Grodno State Medical University
- City Clinical Hospital No. 3 of Grodno
- 期: 卷 4, 编号 1 (2024)
- 页面: 5-14
- 栏目: Original Research
- URL: https://bakhtiniada.ru/cardar/article/view/257367
- DOI: https://doi.org/10.17816/cardar629168
- ID: 257367
如何引用文章
详细
This article provides the experience of examination and treatment of paroxysmal atrial fibrillation patients with concomitant obesity, arterial hypertension and/or ischemic heart disease, who were prescribed levocarnitine in addition to traditional therapy. The addition of levocarnitine in management of atrial fibrillation was found to be capable of reducing the atrial fibrillation burden after cardioversion and improve the functional state of the patients.
作者简介
Tatiana Balabanovich
Grodno State Medical University
编辑信件的主要联系方式.
Email: TatiBo1@yandex.ru
ORCID iD: 0000-0002-5552-8764
SPIN 代码: 8776-7636
MD, Cand. Sci. (Med.), Assistant Professor
白俄罗斯, GrodnoValentina Golyshko
Grodno State Medical University
Email: vgolyshko@inbox.ru
ORCID iD: 0000-0001-9907-6192
SPIN 代码: 3743-3770
MD, Cand. Sci. (Med.), Assistant Professor
白俄罗斯, GrodnoIrina Sinkevich
City Clinical Hospital No. 3 of Grodno
Email: irina5897509@gmail.com
cardiologist
白俄罗斯, GrodnoElen Shkuta
City Clinical Hospital No. 3 of Grodno
Email: ellashkuta@gmail.com
сlinical pharmacologist
白俄罗斯, GrodnoElizaveta Veniadziktova
City Clinical Hospital No. 3 of Grodno
Email: agent.vms@gmail.com
cardiologist
白俄罗斯, GrodnoPavel Baliuk
City Clinical Hospital No. 3 of Grodno
Email: pbalyuk98@mail.ru
cardiologist
白俄罗斯, GrodnoAlexei Knysh
City Clinical Hospital No. 3 of Grodno
Email: alekseiknysh19@ail.com
doctor of ultrasound diagnostics
白俄罗斯, Grodno参考
- Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa945
- Trohman RG, Huang HD, Sharma PS. Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1. Front Cardiovasc Med. 2023;10:1060030. doi: 10.3389/fcvm.2023.1060030
- Vizzardi E, Curnis A, Latini MG, et al. Risk factors for atrial fibrillation recurrence: a literature review. J Cardiovasc Med (Hagerstown). 2014;15(3):235–253. doi: 10.2459/jcm.0b013e328358554b
- DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544–551. doi: 10.1016/j.mayocp.2013.02.007
- Zhao G, Zhang H, Wang Y, et al. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure. Hellenic J Cardiol. 2020;61(2):99–102. doi: 10.1016/j.hjc.2018.08.006
- Kinugasa Y, Sota T, Ishiga N, et al. L-carnitine supplementation in heart failure patients with preserved ejection fraction; a pilot study. Geriatr Gerontol Int. 2020;20(12):1244–1245. doi: 10.1111/ggi.14060
- Dastan F, Talasaz AH, Mojtahedzadeh M, et al. Randomized trial of carnitine for the prevention of perioperative atrial fibrillation. Semin Thorac Cardiovasc Surg. 2018;30:7–13. doi: 10.1053/j.semtcvs.2017.08.006
- Shingu Y, Katoh N, Ooka T, et al. L-carnitine supplementation for the prevention of postoperative atrial fibrillation in aortic valve surgery. Gen Thorac Cardiovasc Surg. 2021;69(11):1460–1466. doi: 10.1007/s11748-021-01616-2
- Astashkin EI, Glezer MG. Cardiac lipotoxic effects of obesity. Arterial Hypertension. 2009;15(3):335–341. (In Russ.) doi: 10.18705/1607-419X-2009-15-3-335-341
- Zhang Y, Fu Y, Jiang T, et al. Enhancing fatty acids oxidation via L-carnitine attenuates obesity-related atrial fibrillation and structural remodeling by activating AMPK signaling and alleviating cardiac lipotoxicity. Front Pharmacol. 2021;12:771940. doi: 10.3389/fphar.2021.771940
- Muszyński P, Bonda TA. Mitochondrial dysfunction in atrial fibrillation-mechanisms and pharmacological interventions. J Clin Med. 2021;10(11):2385. doi: 10.3390/jcm10112385
- Gasparova I, Kubatka P, Opatrilova R, et al. Perspectives and challenges of antioxidant therapy for atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(1):1–14. doi: 10.1007/s00210-016-1320-9
- Sciatti E, Lombardi C, Ravera A, et al.. Nutritional deficiency in patients with heart failure. Nutrients. 2016;8(7):442. doi: 10.3390/nu8070442
- Song X, Qu H, Yang Z, et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. Biomed Res Int. 2017;2017:6274854. doi: 10.1155/2017/6274854
- Trukhan DI. Role and location of L-carnitine in cytoprotection and correction of metabolic processes in patients with metabolic syndrome. Medical Council. 2017;(12):182–187. EDN: ZQTJYB doi: 10.21518/2079-701X-2017-12-182-187
补充文件
